New research suggests that a newer contraceptive method for males, which involves applying lotion once daily, is effective within a few weeks and has few negative effects. The NES/T hormonal solution, which inhibits sperm production, is topically administered to the shoulders once daily. A participant in a phase 2 experiment, out of a total of 222 participants, informed NBC News that the gel solution had a similar texture to hand sanitizer. The guy describes the application as a straightforward process, noting that the only potential negative effects he had were acne and some weight gain. According to statistics given at the Endocrine Society's meeting in Boston, the sperm counts of participants were suitably repressed in the following percentages: 20% within five weeks, 52% by eight weeks, 62% by nine weeks, and 86% after 15 weeks. This information was reported by Gizmodo.
NES/T, named for its key components nestorone and testosterone, was created by scientists at the National Institutes of Health's Contraceptive Development Program. Nestorone, a synthetic derivative of progesterone, reduces the concentrations of fertility-related hormones, such as testosterone, in both the bloodstream and testes. According to Gizmodo, testosterone is included in the gel to preserve consistent hormone levels in men's blood, which helps to temporarily decrease their sex urge, achieve temporary sterility, and minimize any potential negative effects. "We are highly satisfied with the minimal adverse reactions that we have observed," states Diana Blithe, head of the NICHD's Contraceptive Development Program, in an interview. In addition, she was pleasantly astonished by the rapid decline in sperm counts.
According to NBC, researchers define successful contraceptive suppression as reducing the number of sperm in semen to no more than 1 million per millimeter, which is a significant decrease from the previous range of 15 million to 200 million per milliliter. The duration of median suppression was eight weeks. However, as few individuals were not evaluated throughout the period from week four to week eight, the actual median value may be lower. "We are quite satisfied with this outcome. "We believe that this will enhance the appeal of the gel to individuals who were previously unwilling to wait for three months for it to become effective," Blithe explains to Gizmodo. The study team has initiated a Phase 2B experiment with 400 male participants, which has yielded promising first findings. They are now preparing to conduct a Phase 3 trial, and will engage in discussions with the FDA over this matter in the upcoming year. According to the BBC, if all goes as planned, the gel might be available for purchase by the end of the current decade.
NES/T, named for its key components nestorone and testosterone, was created by scientists at the National Institutes of Health's Contraceptive Development Program. Nestorone, a synthetic derivative of progesterone, reduces the concentrations of fertility-related hormones, such as testosterone, in both the bloodstream and testes. According to Gizmodo, testosterone is included in the gel to preserve consistent hormone levels in men's blood, which helps to temporarily decrease their sex urge, achieve temporary sterility, and minimize any potential negative effects. "We are highly satisfied with the minimal adverse reactions that we have observed," states Diana Blithe, head of the NICHD's Contraceptive Development Program, in an interview. In addition, she was pleasantly astonished by the rapid decline in sperm counts.
According to NBC, researchers define successful contraceptive suppression as reducing the number of sperm in semen to no more than 1 million per millimeter, which is a significant decrease from the previous range of 15 million to 200 million per milliliter. The duration of median suppression was eight weeks. However, as few individuals were not evaluated throughout the period from week four to week eight, the actual median value may be lower. "We are quite satisfied with this outcome. "We believe that this will enhance the appeal of the gel to individuals who were previously unwilling to wait for three months for it to become effective," Blithe explains to Gizmodo. The study team has initiated a Phase 2B experiment with 400 male participants, which has yielded promising first findings. They are now preparing to conduct a Phase 3 trial, and will engage in discussions with the FDA over this matter in the upcoming year. According to the BBC, if all goes as planned, the gel might be available for purchase by the end of the current decade.
